| DC46565 |
PD-1-IN-20
|
PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. PD-1-IN-1 is an inhibitor of programmed cell dealth-1 (PD-1) extracted from patent WO 2015033299 A1, compound example 4. |
| DC46218 |
PD-1-IN-17 TFA
|
PD-1-IN-17 TFA is a programmed cell death-1 (PD-1) inhibitor extracted from patent WO2015033301A1, Compound 12, inhibits 92% splenocyte proliferation at 100 nM. |
| DC44156 |
TPP-1 TFA
|
TPP-1 TFA is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 TFA binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 TFA inhibits human tumor growth in vivo via reactivating T-cell function. |
| DC44155 |
TPP-1
|
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function. |
| DC42066 |
Human PD-L1 inhibitor III
|
Human PD-L1 inhibitor III is a human PD-L1 inhibitor. |
| DC41989 |
Human PD-L1 inhibitor V
|
Human PD-L1 inhibitor V, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1. |
| DC41988 |
Human PD-L1 inhibitor IV
|
Human PD-L1 inhibitor IV, a polypeptide, is a competitive human PD-1 protein inhibitor with a Kd value of 1.38 μM. Human PD-L1 inhibitor IV inhibits the interaction of hPD-1/hPD-L1. |
| DC41982 |
Human PD-L1 inhibitor II
|
Human PD-L1 inhibitor II is a potent PD-L1 inhibitor with anti-cancer activity. |
| DC28554 |
PD-1/PD-L1-IN 5
|
PD-1/PD-L1-IN 5 is a PD-1/PD-L1 protein/protein interaction inhibitor extracted from patent WO2017222976A1, compound Example 1, has an IC50 of ≤100 nM. |
| DC28140 |
PD-1/PD-L1-IN 3 TFA
|
PD-1/PD-L1-IN 3 TFA is a PD-1/PD-L1 interaction inhibitor extracted from patent WO2014151634A1, compound 1. PD-1/PD-L1-IN 3 TFA inhibits the binding of human PD-1 to PD-Ll with an IC50 of 9 nM. |
